Although accepted agents in chorioamnionitis and preterm birth, the role of
Ureaplasma
species (spp.) in inflammation-driven morbidities of prematurity, including the development of bronchopulmonary dysplasia, remains controversial. To add to scarce
in vitro
data addressing the pro-inflammatory capacity of
Ureaplasma
spp., pulmonary epithelial-like A549 cells and human pulmonary microvascular endothelial cells (HPMEC) were incubated with
Ureaplasma (U
.
) urealyticum
,
U
.
parvum
, and
Escherichia coli
lipopolysaccharide (LPS).
Ureaplasma
isolates down-regulated caspase mRNA levels in A549 cells (caspase 8:
p
<0.001, 9:
p
<0.001, vs. broth), while increasing caspase protein expression, enzyme activity, and cell death in HPMEC (active caspase 3:
p
<0.05, caspase 8:
p
<0.05, active caspase 9:
p
<0.05, viability:
p
<0.05). LPS, contrarily, induced caspase mRNA expression in HPMEC (caspase 3:
p
<0.01, 4:
p
<0.001, 5:
p
<0.001, 8:
p
<0.001, vs. control), but not in A549 cells, and did not affect enzyme activity or protein levels in either cell line. LPS, but neither
Ureaplasma
isolate, enhanced mRNA expression of pro-inflammatory interleukin (
IL)-6
in both A549 (
p
<0.05, vs. control) and HPMEC (
p
<0.001) as well as tumor necrosis factor-α (
p
<0.01),
IL-1β
(
p
<0.001), and
IL-8
(
p
<0.05) in HPMEC. We are therefore the first to demonstrate a differential modulation of pulmonary caspases by
Ureaplasma
spp.
in vitro
.
Ureaplasma
-driven enhanced protein expression and activity of caspases in pulmonary endothelial cells result in cell death and may cause structural damage. Down-regulated caspase mRNA in pulmonary epithelial cells, contrarily, may indicate
Ureaplasma
-induced inhibition of apoptosis and prevent effective immune responses. Both may ultimately contribute to chronic
Ureaplasma
colonization and long-term pulmonary inflammation.